Recro Pharma, Inc. (REPH) SEC Filing 8-K Material Event for the period ending Friday, November 12, 2021

Recro Pharma, Inc.

CIK: 1588972 Ticker: REPH

View differences made from one to another to evaluate Recro Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Recro Pharma, Inc..


Assess how Recro Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Recro Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Recro Pharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: REPH
CIK: 1588972
Form Type: 8-K Corporate News
Accession Number: 0000950170-21-004225
Submitted to the SEC: Fri Nov 12 2021 7:09:50 AM EST
Accepted by the SEC: Fri Nov 12 2021
Period: Friday, November 12, 2021
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: